Medical Device | March 22, 2022
Thermo Fisher Scientific to showcase global innovation at DCAT Week 2022
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
Expanded capabilities across pharma services network accelerate innovation and enhance productivity for customers
The facility registration, along with DMF registration and GMP certification provides peace of mind to clients looking to use our iPSCs for clinical and commercial use in the United States, Japan, and other global markets
RNA, cell & gene therapies, artificial intelligence, CRISPR and oncology-related deals dominate the landscape
The RTP manufacturing facility will support the company's clinical studies and early commercial launch in North America and Europe
Optimized for pharma/biopharma to deliver a deeper understanding of cellular function
It is the first CAR T Therapy approved for the treatment of multiple myeloma in Japan
Under the terms of the agreement, Mammoth Biosciences will receive an upfront payment of USD 40 million, potential future payments of more than one billion USD upon successful achievement of certain research, development, and commercial milestones
This next-generation CAR T construct was designed to improve the tolerability profile of conventional CD19 CAR Ts and developed in the laboratory of James N. Kochenderfer, M.D., at the National Cancer Institute, part of the NIH, the same laboratory that discovered axicabtagene ciloleucel
T-Charge, a next-generation platform that aims to revolutionize CAR-T cell therapy, will serve as the foundation for various investigational CAR-T therapies
Focused medicines company delivering strong operational performance. Building depth in five core therapeutic areas, strength in technology platforms, and a balanced geographic footprint
Subscribe To Our Newsletter & Stay Updated
